OTCMKTS:RGIN Regenicin (RGIN) Stock Price, News & Analysis $0.0001 0.00 (0.00%) As of 10/13/2025 09:30 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Regenicin Stock (OTCMKTS:RGIN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Regenicin alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.0001▼$0.0001Volume10,000 shsAverage Volume10,000 shsMarket Capitalization$16.58 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey. Read More Receive RGIN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regenicin and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RGIN Stock News HeadlinesHistoryOctober 20, 2024 | npr.orgNRegenicin, Inc. (RGIN)September 5, 2024 | finance.yahoo.comOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading strategy that could help accelerate your retirement goals. It’s called the Retirement Trade — a short-term approach designed to capture consistent morning setups without waiting months for results.October 16 at 2:00 AM | Base Camp Trading (Ad)LGBT+ History Month - Teaching ResourcesMay 3, 2024 | bbc.co.ukJohn Kerry praises Biden for preventing 'uncontrolled war in many regions'January 19, 2024 | foxnews.comHistory of Walmart: Timeline and FactsDecember 9, 2023 | thestreet.comHeavy rains trigger floods and landslides in India's Himalayan region, leaving at least 48 deadAugust 22, 2023 | foxnews.comUkraine army attacks Russian forces in southern Zaporizhzhia regionJune 13, 2023 | bbc.comBSee More Headlines RGIN Stock Analysis - Frequently Asked Questions How have RGIN shares performed this year? Regenicin's stock was trading at $0.0001 at the beginning of the year. Since then, RGIN stock has increased by 0.0% and is now trading at $0.0001. How were Regenicin's earnings last quarter? Regenicin Inc. (OTCMKTS:RGIN) issued its quarterly earnings results on Wednesday, August, 19th. The company reported $0.00 earnings per share (EPS) for the quarter. How do I buy shares of Regenicin? Shares of RGIN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Regenicin own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regenicin investors own include Energous (WATT), Cheniere Energy (LNG), Vital Therapies (VTL), Xerox (XRX), Allergan (AGN) and Leafbuyer Technologies (LBUY). Company Calendar Last Earnings8/19/2020Today10/16/2025Fiscal Year End9/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryMedical Equipment Current SymbolOTCMKTS:RGIN CIK1412659 Webwww.regenicin.com Phone(732) 757-5500FaxN/AEmployees3Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares165,770,000Free FloatN/AMarket Cap$16.58 thousand OptionableNot Optionable BetaN/A Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (OTCMKTS:RGIN) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersIs *BSEM* Oversold??BioStem Technologies Inc. (OTC: BSEM) is emerging as one of the most exciting MedTech stories of 2025. The com...Huge Alerts | SponsoredRefund From 1933: Trump’s Reset May Create Instant WealthFed vs. Trump - A War With American Wealth At Stake The Fed's defiance of Trump thickens the plot to contro...American Hartford Gold | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredOptions Pro Reveals His #1 Retirement Income TradeThe current market is creating a perfect setup for my favorite trading strategy — one that doesn’t rely on ris...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regenicin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regenicin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.